The future of comparative effectiveness and relative efficacy of drugs: An international perspective

Journal of Comparative Effectiveness Research

Volumn 4, Issue 4, 2015, Pages 419-427

  Messner, Donna A ^a   Towse, Adrian ^b   Mohr, Penny ^c   Garau, Martina ^b  

^a Center for Medical Technology Policy   (United States)

^b OFFICE OF HEALTH ECONOMICS   (United Kingdom)

^c Outcomes Research Institute   (United States)

Author keywords

adaptive licensing; comparative effectiveness research; drug development; effectiveness; efficacy; EMA; FDA; HTA; PCORI; postauthorization efficacy studies; relative effectiveness; relative efficacy

Indexed keywords

COMPARATIVE EFFECTIVENESS; DATA MINING; DECISION MAKING; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; EUROPE; HEALTH CARE CONCEPTS; HEALTH CARE DELIVERY; HUMAN; LICENSING; PATIENT CARE; PRIORITY JOURNAL; RELATIVE EFFECTIVENESS; REVIEW; RISK BENEFIT ANALYSIS; UNITED STATES; BIOMEDICAL TECHNOLOGY ASSESSMENT; DRUG DEVELOPMENT; ECONOMICS; INTERNATIONAL COOPERATION; PROCEDURES;

PRESCRIPTION DRUG;

COMPARATIVE EFFECTIVENESS RESEARCH; DRUG DISCOVERY; HUMANS; INTERNATIONALITY; PRESCRIPTION DRUGS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84939451980     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.15.8     Document Type: Review

References (8)

1. Messner DA, Mohr P, Towse A. Futurescapes: evidence expectations in the US for CER for drugs in 2020. J. Comp. Eff. Res. 4(4), 385-400 (2015).
2. Towse A, Garau M, Mohr P, Messner DA. Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. J. Comp. Eff. Res. 4(4), 401-418 (2015).
3. Institute of Medicine, Committee on Comparative Effectiveness Research Prioritization. Initial National Priorities for Comparative Effectiveness Research. The National Academies Press, Washington, DC, USA (2009).
4. High Level Pharmaceutical Forum. Final conclusions and recommendations of the high level pharmaceutical forum, p. 6. http://ec. europa. eu/enterprise/sectors/healthcare/files/docs
5. Jönsson B. Relative effectiveness and the European pharmaceutical market. Eur. J. Health Econ. 12(2), 97-102 (2011).
6. Thorpe KE, Zwarenstein M, Oxman AD et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J. Clin. Epidemiol. 62(5), 464-475 (2009).
7. Loudon K, Zwarenstein M, Sullivan F, Donnan P, Treweek S. PRECIS-2: a tool to improve the applicability of randomized controlled trials. Trials 14(Suppl. 1), O28 (2013).
8. Lauer MS, D'Agostino RB Sr. The randomized registry trial-the next disruptive technology in clinical research? N. Engl. J. Med. 369(17), 1579-1581 (2013).